Reuters: Regulatory News: EU agency endorses Bristol, Astra diabetes drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

EU agency endorses Bristol, Astra diabetes drug Apr 20th 2012, 13:25 LONDON, April 20 | Fri Apr 20, 2012 9:25am EDT LONDON, April 20 (Reuters) - European regulators on Friday backed approval of a new diabetes drug from AstraZeneca and Bristol-Myers Squibb that was rejected last year in the United States. Dapagliflozin belongs to a new class of diabetes drugs designed to allow more sugar to be excreted with urine and has the potential to be the first to treat the disease independent of the hormone insulin. The European Medicines Agency also endorsed new drugs from Novartis and Takeda.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions